Losartan Liquid Formulations and Methods of Use
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2021/054054, filed Oct 7, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,890,273 | Losartan Liquid Formulations and Methods of Use In force · Medium confidence | Scienture, LLC | In force | Medium confidence | ||
| US 12,156,869 | Losartan Liquid Formulations and Methods of Use In force · Medium confidence | Scienture, LLC | In force | Medium confidence | ||
| US 12,605,365 | Losartan Liquid Formulations and Methods of Use In force · Low confidence | Scienture, LLC | In force | Low confidence | ||
| Application 19/080,602 | Losartan Liquid Formulations and Methods of Use Pending Not granted | Scienture, LLC | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Scienture, LLC.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.